One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is VIVUS Inc. (VVUS). This Medical – Biomedical/Genetics stock has actually seen loss estimates narrow over the past month for …
J.P.Morgan adjusted its estimates for Vivus Inc., (NASDAQ: VVUS) to reflect the company's quarterly results ... The upside catalysts to the stock include earlier than expected approval of Qnexa or a product partnership. The firm …
Stock market news today is dominated by Microsoft, Nokia, Verizon, and the rest of these stocks, reports and mergers you have to stay on top of ...
Vivus’s Qnexa, the first of three new anti-obesity drugs under FDA review this year, came before one of the agency’s advisory committees today — and it was a swing and a miss. The panel recommended against …
However, given the uncertainty of this issue, investors are likely to remain on the sidelines and focus on the drug's launch ramp before bidding up the stock. Expect VVUS shares to lift slightly today on the news that Qsymia is the first of a …